Stock DNA
Pharmaceuticals & Biotechnology
USD 78 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
0.75
-238.43%
10.74
Total Returns (Price + Dividend) 
Apyx Medical Corp. for the last several years.
Risk Adjusted Returns v/s 
News

Apyx Medical Corp. Hits New 52-Week High of $3.99
Apyx Medical Corp. has achieved a new 52-week high of USD 3.99, reflecting a significant increase in its stock price over the past year. With a market capitalization of USD 78 million, the company operates in a competitive sector, facing challenges such as negative return on equity and moderate leverage.
Read More
Apyx Medical Corp. Hits New 52-Week High of $3.65, Up 109%
Apyx Medical Corp. has achieved a new 52-week high of USD 3.65, reflecting a significant increase over the past year. The company, with a market capitalization of USD 78 million, remains unprofitable and exhibits a high price-to-book ratio, indicating a premium valuation amidst its volatility in the pharmaceuticals and biotechnology sector.
Read More
Apyx Medical Corp. Hits New 52-Week High of $3.49
Apyx Medical Corp. has achieved a new 52-week high of USD 3.49, reflecting a significant increase in stock performance over the past year. With a market capitalization of USD 78 million, the company operates in a competitive pharmaceuticals and biotechnology sector, despite currently facing losses.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 11 Schemes (12.72%)
Held by 17 Foreign Institutions (2.86%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
YoY Growth in quarter ended Jun 2025 is -5.79% vs -11.03% in Jun 2024
YoY Growth in quarter ended Jun 2025 is 43.94% vs -560.00% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is -8.03% vs 17.53% in Dec 2023
YoY Growth in year ended Dec 2024 is -24.87% vs 18.88% in Dec 2023






